Text Size

Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523AM2) (COMPLETED)

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00423670
First received: January 17, 2007
Last updated: March 15, 2013
Last verified: March 2013
History of Changes
Results First Received: May 13, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Chronic Hepatitis C
Interventions: Drug: boceprevir (SCH 503034)
Drug: peginterferon-alfa 2b (PegIntron)
Drug: ribavirin
Drug: ribavirin (low-dose)

  Participant Flow
  Show Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Arm 1. PEG +RBV for 48 Wks (Part I)

PegIntron (1.5 μg/kg QW) plus ribavirin (800 to 1400 mg/day) for 48 weeks.

• Participants with detectable HCV-RNA levels after 24 weeks of treatment had to receive 24 weeks of PegIntron, ribavirin and boceprevir (800 mg TID) for 24 additional weeks. Total treatment duration was up to 54 weeks.
Arm 2. PEG + RBV + BOC for 28 Wks (Part I) Boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 28 weeks.
Arm 3. PEG + RBV + BOC (From Wk 4) for 24 Wks (Part I) PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks lead in followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 24 weeks.
Arm 4. PEG +RBV + BOC for 48 Wks (Part I) Boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 48 weeks.
Arm 5. PEG + RBV+ BOC (From Wk 4) for 44 Wks (Part I) PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks lead in followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 44 weeks.
Arm 6. PEG + RBV + BOC for 48 Wks (Part II) PegIntron (1.5 μg/kg QW), ribavirin (800 to 1400 mg/day) and boceprevir (800 mg TID) for up to 48 weeks.
Arm 7. PEG +Low-dose RBV + BOC for 48 Wks (Part II) PegIntron (1.5 μg/kg QW), ribavirin (400 to 1000 mg/day) and boceprevir (800 mg TID) for up to 48 weeks.
Total Total of all reporting groups

Baseline Measures
    Arm 1. PEG +RBV for 48 Wks (Part I)     Arm 2. PEG + RBV + BOC for 28 Wks (Part I)     Arm 3. PEG + RBV + BOC (From Wk 4) for 24 Wks (Part I)     Arm 4. PEG +RBV + BOC for 48 Wks (Part I)     Arm 5. PEG + RBV+ BOC (From Wk 4) for 44 Wks (Part I)     Arm 6. PEG + RBV + BOC for 48 Wks (Part II)     Arm 7. PEG +Low-dose RBV + BOC for 48 Wks (Part II)     Total  
Number of Participants  
[units: participants]
 		  104     107     103     103     103     16     59     595  
Age [1]
[units: years]
Mean ± Standard Deviation 		  48.3  ± 6.9     46.4  ± 8.0     47.7  ± 7.4     46.7  ± 8.8     47.6  ± 8.3     50.3  ± 8.5     48.7  ± 5.8     47.5  ± 7.7  
Gender [2]
[units: participants]
 		               
Female     34     44     52     40     45     7     18     240  
Male     70     63     51     63     58     9     41     355  
[1] Overall age characteristics were displayed for Arm 1 through Arm 7. Participants from Arm 1 (Part I) who had detectable HCV-RNA at TW 24, had the option to switch to a new arm, Arm 8.
[2] Overall gender characteristics were displayed for Arm 1 through Arm 7. Participants from Arm 1 (Part I) who had detectable HCV-RNA TW 24, had the option to switch to a new arm, Arm 8.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Sustained Virologic Response (SVR)   [ Time Frame: From follow-up week (FW) 24 up to end of follow-up (EOF) ]
  Show Outcome Measure 1

2.  Secondary:   Number of Participants With SVR Based on a 4-week lead-in Treatment With PegIntron and Ribavirin   [ Time Frame: From FW 24 up to EOF ]
  Show Outcome Measure 2

3.  Secondary:   Number of Participants With SVR Based on Duration of Boceprevir Treatment   [ Time Frame: From FW 24 up to EOF ]
  Show Outcome Measure 3

4.  Secondary:   Number of Participants Negative for HCV-RNA at FW 12   [ Time Frame: At FW 12 ]
  Show Outcome Measure 4

5.  Secondary:   Number of Participants Negative for HCV-RNA at 72 Weeks Post Randomization   [ Time Frame: 72 weeks post randomization ]
  Show Outcome Measure 5

6.  Secondary:   Number of Participants With an Early Virologic Response (EVR) That Achieved SVR   [ Time Frame: At TW 12, and at FW 24 up to EOF ]
  Show Outcome Measure 6

7.  Secondary:   Number of Participants With a Virologic Response at Follow-up Week 12 That Achieved SVR   [ Time Frame: At FW 12 and FW 24 up to EOF ]
  Show Outcome Measure 7

8.  Secondary:   Number of Participants With a Virologic Response at 72 Weeks Post Randomization That Achieved SVR   [ Time Frame: At FW 24 up to EOF and at 72 weeks post randomization ]
  Show Outcome Measure 8


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Vice President, Late Stage Development Group Leader
Organization: Merck, Sharp and Dohme
e-mail: ClinicalTrialsDisclosure@merck.com


No publications provided by Merck

Publications automatically indexed to this study:


Responsible Party: Vice President, Late Stage Development Group Leader, Merck Sharp & Dohme
ClinicalTrials.gov Identifier: NCT00423670     History of Changes
Other Study ID Numbers: P03523, EudraCT No. 2006-002543-92
Study First Received: January 17, 2007
Results First Received: May 13, 2011
Last Updated: March 15, 2013
Health Authority: United States: Food and Drug Administration